Experimental suppression of FKBP51—genetically or pharmacologically—enhances the levels of autophagic markers LC3 and SQSTM1/p62 and reduces mHTT accumulation in HD NSCs and mouse models (Bailus et al., 2021). The gene discussed is SQSTM1; the disease is Huntington disease.